Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
Front Pharmacol
.
2018 Apr 19:9:381.
doi: 10.3389/fphar.2018.00381.
eCollection 2018.
Authors
Javier Durán
1
,
Manuel Estrada
1
Affiliation
1
Program of Physiology and Biophysics, Faculty of Medicine, University of Chile, Santiago, Chile.
PMID:
29726548
PMCID:
PMC5917040
DOI:
10.3389/fphar.2018.00381
No abstract available
Keywords:
ActRIIA/B receptors; anabolic steroids; bimagrumab; myostatin/activin; skeletal muscle.
Publication types
Comment